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Introduction
Salivary gland tumors are rare, accounting for between 2.0% 
and 5.6% of all neoplasms of the head and the neck.1 Among 
them, pleomorphic adenoma (PA) is the most common tumor, 
accounting for 60%–70% of all neoplasms.1,2 In contrast, basal 
cell adenoma (BCA) is a rare, benign epithelial neoplasm that 
comprises 1%–3% of the epithelial salivary gland tumors.1,3 
PA and BCA have numerous similarities. They are com-
posed of luminal and abluminal cells, and both have a good 
prognosis.1–3
In tumor biology, the blood and lymphatic vessels are 
important components of the tumor microenvironment. The 
blood and lymphatic vessels of tumors are newly formed from 
the preexisting host vessels in response to stimulation by 
pro-angiogenic and pro-lymphangiogenic factors expressed 
by tumor cells, such as the vascular endothelial growth 
factor (VEGF). Tumor cells establish a specific stromal 
microenvironment that fosters tumor growth, which involves 
blood/lymph angiogenesis.4 Studies have shown that trigger-
ing angiogenesis and lymph angiogenesis are crucial events in 
tumor growth.5,6
Studies indicate that the processes of proliferation and 
angiogenesis delineate the biology of individual tumors.7 
Many cell cycle proteins have been employed as cell prolif-
eration biomarkers, of which Ki-67 and Mcm-2 are the most 
widely used.8,9 Mcm-2 is present in the early G1 phase of 
the cell cycle.8,10 For this reason, research currently suggests 
that Mcm-2 is a more specific and sensitive cell proliferation 
marker than Ki-67.8,9,11
The blood and lymphatic vascularization of malignant 
tumors has been widely investigated, mostly concerning 
angiogenesis and antiangiogenic therapy. However, these 
studies have focused on the malignant processes, whereas 
few studies have been devoted to benign tumors. There are 
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a few studies concerning blood and lymphatic vasculariza-
tion in PA,12,13 while there has been no such investigation for 
BCA. Therefore, the purpose of this study was to compare the 
vascular/lymphatic microenviroment in PA and BCA. Using 
immunochemistry, a comparison was made by measuring the 
microvessel density (MVD) using antibodies for CD34 and 
CD105, lymphatic vascular density (LVD) using the D2–40 
antibody, and growth factor using the VEGF antibody. In 
addition, immunohistochemical staining for the Mcm-2 anti-
gen was conducted to evaluate cell proliferation in PA and 
BCA tumors.
Materials and Methods
The present study involved 30 cases of PA and 13 cases of 
BCA. Two pathologists reviewed all diagnoses using 5-µm 
sections obtained from formalin-fixed, paraffin-embedded 
samples and stained with hematoxylin and eosin. Demographic 
and clinical information were obtained from the patients’ med-
ical records. The study protocol was approved by the Commit-
tee of Ethics in Research of the Faculty of Dentistry at the São 
Leopoldo Mandic Institute and Research Center.
Immunohistochemistry. One paraffin block from each 
case was chosen for immunohistochemical staining with the 
following antibodies (Table 1): anti-CD34 and anti-CD105 
to detect blood vessels; anti-D2–40 to detect lymphatic ves-
sels; anti VEGF to detect vascular growth factors; and anti-
Mcm-2 to detect cell proliferation.
The 5-µm sections were deparaffinized and hydrated, and 
endogenous peroxidase activity was quenched by immersing 
the slides in 3% hydrogen peroxide. Antigen retrieval (AR) 
was achieved by immersing the slides in boiling citrate buf-
fer (pH 6.0) for all antibodies except for anti-CD105, which 
was performed using 0.4% pepsin for 30 minutes (Table 1). 
Only the anti-CD105 sections were incubated at 37 °C with a 
serum-free protein blocking solution (code x0909, Dako, SA) 
for 30 minutes. Subsequently, the sections were incubated with 
the primary antibody overnight at 4 °C, followed by EnVision 
polymer HRP and Envision+ (code K1491, DAKO) for one 
hour at 37 °C. The sections were stained for five minutes at 
37 °C with 3,3'-diaminobenzidine tetrahydrochloride (DAB) 
and counter-stained with hematoxylin. A negative control was 
obtained by omitting the primary antibody. No staining was 
observed in this section.
density of blood and lymphatic microvessels. Immuno-
histochemical staining for CD34, CD105, and D2–40 was inter-
preted by two pathologists using a double-headed microscope. 
Observation of vascularization was performed throughout the 
whole specimen, but the most cellular areas were chosen for count-
ing of the vasculature. To assess the number of vessels, images 
were obtained from five fields (hotspots) per case (40 × objective, 
0.44 mm field diameter) using a camera attached to an Olympus 
CX30 microscope. The images were analyzed with Imagelab anal-
ysis software (version 2.4), which allowed manual segmentation 
of the target vessels. The blood and lymphatic microvascular den-
sities obtained from CD34, CD105, and D2–40 immunostaining 
were expressed as the mean number of intratumoral microvessels 
counted. There was no restriction regarding the size of a count-
able microvessel; however, vessels with muscular walls and areas 
observed to be necrotic were excluded.
growth factor. Growth factor immunohistochemical 
reactions to VEGF were used in the initial evaluation to verify 
the expression pattern of the sections stained with the anti-
body. The labeled sections were evaluated qualitatively and 
semiquantitatively. The qualitative analysis was performed via 
the evaluation of the positive cells from different areas in all 
cases. The relative number of neoplastic cells was considered 
in relation to all neoplastic cells observed for each stained sec-
tion. When the number of positive cells was more than 10%, 
table 1. details of the antibodies used for immunohistochemistry.
SPeCifiCitY CLone DiLution SouRCe BuffeR 
(AR)
Cd34 QBend 10 1:50 dako* Citrate
Cd 105 sng 1:10 dako* Pepsin
d2–40 d2–40 1:200 dako* tris-
edta
VegF sc-7269 1:100 santa Cruz** Citrato
MCM-2 sP85 1:200 spring*** Citrate
notes: *dako Corporation, glostrup, denmark. **santa Cruz Biotechnogy, 
inc., santa Cruz, Ca, Usa. ***spring Bioscience, Pleasanton, Ca, Usa.
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figure 1. immunostaining of blood and lymphatic vessels in pleomorphic 
adenoma (Pa) and basal cell adenoma (BCa). Many Cd34-positive 
blood vessels are seen in Pa and BCa (A, B). a small number of 
Cd105-positive vessels are observed in BCa and Pa (C, D). d2–40-
positive lymphatic vessels are found in the tumor margins of Pa, while 
intratumoral d2–40-positive lymphatic vessels were found in BCa (e, f). 
Bars: A, B, D, e, f = 266 µm; C = 100 µm.
Vascularization in basal cell adenoma and pleomorphic adenoma
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the case was considered positive. A grading system based on 
reactivity percentage was assigned on a scale from 0 to 3. Less 
than 10% cell reactivity was assigned 0; 10%–25% cell reac-
tivity was assigned 1; 25%–50% cell reactivity was assigned 2; 
and reactivity greater than 50% was assigned 3.
cell proliferation. The proliferative indexes of Mcm-2 
were obtained by calculating the percentage of cells with posi-
tive nuclear staining in a total of 500 tumor cells examined by 
microscopy at 40× magnification.
statistical analysis. Statistical analysis of the data was 
performed using GraphPad Prism 4® statistical software; the 
Kolmogorov–Smirnov test was used for evaluation of normal-
ity. Comparison between two groups of variables with non-
normal distribution was performed using the Mann–Whitney 
test. VEGF staining was evaluated using a score, with the 
statistical test employed being the Wilcoxon. The level of sig-
nificance in both tests was set at 5%.
results
The PA group included 20 women and 10 men. Nineteen of 
the tumors were located in the palate, eight in the parotid, 
and three in the submandibular glands. The average age of 
the patients was 38 years. The BCA group included seven 
women and five men, as well as one person whose gender was 
not listed. The average age was 62 years, with 12 tumors being 
located in the parotid and 1 tumor in the glands of the upper 
lip. Data were not available for one BCA and one PA case.
Microvascular density assessed using anti-cd34 and 
anti-cd105. CD34-positive staining revealed high vascu-
larity in both tumor types. In PA, the vessels were detected 
mostly in cellular-rich areas (mean = 6.33, SD = 4.02), 
whereas in BCA the vessels were dispersed throughout the 
tumors (mean = 12.23, SD = 3.28). There was a significant 
difference between PA and BCA in terms of the MVD for 
CD34 (P = 0.001) (Figs. 1A, 1B, and 2).
When assessing MVD using anti-CD105 staining, 
a few small, positively stained vessels were detected in the 
cellular-rich areas of PA (mean = 0.47, SD = 1.17), while 
in BCA the number of positive vessels was slightly higher, 
with them being widely spread throughout the entire tumor 
(mean = 4.69, SD = 3.22). A significant difference was also 
observed between the two groups of tumors (P = 0.0001) 
(Figs. 1C, 1D, and 2).
lymphatic vessel density. In PA, D2–40-positive lym-
phatic vessels were mostly concentrated in the tumor capsules, 
with small intratumoral lymphatic vessels being infrequently 
observed (mean = 0.34, SD = 0.44) (Figs. 1E, 1F, and 2). The 
lymphatic vessels in BCA were also identified at the tumor 
margin, with a small increase observed in the number of 
intratumoral vessels compared to that of PA (mean = 1.83, 
SD = 1.53). Comparison of the two groups showed that the 
difference in LVD was significant (P = 0.0004).
growth factor. VEGF positivity was observed in both 
the nuclei and cytoplasm. In PA, a remarkably heterogeneous 
VEGF immunoreactivity was observed, alternating from weak 
or negative to positive or intense. Immunoreactivity was most 
marked in the epithelial cells and rarely seen in mioepithe-
lial cells. In 13 cases (43%), the cells were negative or showed 
less than 10% reactivity (score 0); 9 cases (30%) had a score of 
1; 5 cases (17%) showed 25%–50% reactivity (score 2); and 3 
cases (10%) scored 3 (Figs. 3C and 4).
All BCA tumors revealed a strong positivity to VEGF, 
with an immunoreaction of more than 50% (score 3) (Figs. 3D 
and 4). Immunoreactivity was observed in epithelial cells, 
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figure 3. histopathology of Pa (A) and BCa (B). in Pa, few tumor cells 
were weakly stained for VegF (C), and in BCa strong positivity was 
detected for VegF (D). Bars: A, B = 160 µm; C, D = 80 µm.
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figure 2. Box and whisker plots of lymphatic vessel density (lVd) and microvessel density (MVd) in pleomorphic adenoma (Pa) and in basal cell 
adenoma (BCa) (n = 30 and 13, respectively) determined using Cd34, Cd105, and d2–40 antibodies.
Soares et al
20 CliniCal MediCine insights: Pathology 2015:8
mostly in the basal layer. A significant difference was observed 
in VEGF positivity between PA and BCA (P = 0.0001).
Proliferative index. No or a small number of Mcm-2- 
positive cells were detected in both PA (mean = 13.23, 
SD = 11.63) and BCA (mean = 12.85, SD = 10.35). No sig-
nificant difference was found between the Mcm-2 prolifera-
tive indexes of the tumors (P = 0.9948) (Fig. 2).
discussion
The stromal microenvironment plays a critical role in tumor 
biology, with the blood and lymphatic vessels found within 
the tumor tissues being key components of the tumor micro-
environment. Tumor-associated angiogenesis is an essential 
pathophysiological phenomenon for sustaining the viability of 
tumor cells during tumor progression.4,14,15 However, infor-
mation is lacking on the role of angiogenesis and lymphatic 
distribution in benign tumors.
The role of angiogenesis in the onset and progression 
of salivary gland malignancies is well recognized,14 with an 
angiogenic switch having been reported during the malig-
nant transformation of pleomorphic adenoma to carcinoma 
ex-pleomorphic adenoma.14 Previous studies from our group 
have shown that vascularization in PA is composed mainly 
of preexisting vessels in a positive correlation to the cellular 
density of the tumor, where the most cellular-rich areas have 
the highest vascular density.12
The present study detected a small increase in vasculariza-
tion from preexisting vessels, with a greater increase in newly 
formed vessels in BCA compared to PA, which was observed 
in the comparison of the MVD obtained using CD34 and 
CD105. This difference could be attributed to the diversity of 
the stroma observed in PA tumor, in which high vasculariza-
tion is not required in myxoid and condroid areas. In contrast, 
BCA is a cellular-rich tumor containing minimal stroma – 
and hence the need for increased vascularity – and indicating 
that the preexisting vessels were insufficient for maintaining 
the tumor cells, thus requiring the formation of new vessels. 
These results confirm our previous studies, in which it was 
suggested that the degree of vascularization in benign salivary 
tumors depends on cell density, most likely due to cellular-rich 
tumors requiring more oxygen in order to support metabolic 
demands.
The ability of tumor cells to induce angiogenesis var-
ies greatly depending on the type of neoplastic cell.16,17 The 
angiogenic switch has been reported to be induced primarily 
by malignant cells14,16,18; however the role of this switch is not 
well understood in benign tumors. The angiogenic switch can 
be analyzed by immunohistochemistry for CD105, which is 
expressed by proliferating endothelial cells, making CD105 
a good marker for newly formed vessels.19 The current study 
detected few CD105-positive vessels in PA, indicating the 
absence of an angiogenic switch in this type of tumor. In con-
trast, CD105-positive vessels were detected more frequently 
in BCA, suggesting that an angiogenic switch was occurring 
in this benign tumor.
Some growth factors play a crucial role in the regulation 
of blood vessel formation, with VEGF-A (commonly named 
VEGF) being among these.20,21 In the present study, VEGF 
positivity confirms the presence of an increased vasculariza-
tion in BCA when compared to PA.
Lymphatic vessels play an important role in maintaining 
fluid balance and tissue homeostasis, as well as being a note-
worthy component of the immune system.22 Tumor research 
has focused on lymphatic vessels, as they represent the main 
route for metastases to the lymph nodes. However, the conse-
quence of tumor-associated lymphangiogenesis in the viability 
of tumor cells is unclear.23 A high lymphatic vessel density 
seems to be an indicator of the risk of lymph node metastasis 
in cutaneous melanoma, head and neck squamous cell carci-
noma, and squamous cell carcinoma of the cervix.24,25 In con-
trast, no intratumoral lymphatic networks have been reported 
for other carcinomas, such as those of breast, ovarian, endo-
metrial, and lung.26,27 No significant difference in lymphatic 
vessel density of high-risk salivary gland tumors and low/
moderate-risk salivary gland carcinomas has been observed 
with regard to nodal metastasis.28
The benign salivary gland tumors PA and recurrent 
pleomorphic adenoma have been reported to have very few, 
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figure 4. Box and whisker plots of VegF and Mcm-2 expression in pleomorphic adenoma (Pa) and basal cell adenoma (BCa) (n = 30 and 13, 
respectively).
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if any, intratumoral lymphatic vessels,12 with the present 
study finding similar results. However, this study did detect 
a small number of lymphatic vessels in BCA. The function of 
the lymphatic vessels is critically dependent upon the compo-
sition, geometry, and integrity of the extracellular matrix.29 
Therefore, in a previous study performed by our group, the 
stroma was suggested as a possible explanation for the absence 
of intratumoral lymphatic vessels in PA, in terms of it possibly 
collapsing the lymphatic vessels and/or pushing the preexist-
ing vessels outside the tumor.2,12 Moreover, a possible expla-
nation for the presence of more lymphatic vessels in BCA than 
PA found in the present study could be that BCA has a scarce 
stroma, in which these vessels are presented.
Although a difference in vascularization between PA and 
BCA was observed in the current study, the cell proliferation 
indices obtained using Mcm-2 staining were similar, indicat-
ing that both tumors have the same cell proliferation features. 
Indeed, PA and BCA have the same biological behavior in 
terms of slow growth and a low risk of recurrence or malig-
nant transformation.1,3
In conclusion, despite the fact that PA and BCA are 
considered part of the same spectrum of differentiation, these 
tumors are different with regard to vascularization, as demon-
strated by immunohistochemistry for CD34, CD105, D2–40, 
and VEGF.
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